PubMed=23161805; DOI=10.1002/emmm.201201973; PMCID=PMC3569650
Jacquet L., Stephenson E.L., Collins R., Patel H., Trussler J., Al-Bedaery R., Renwick P.J., Ogilvie C.M., Vaughan R., Ilic D.
Strategy for the creation of clinical grade hESC line banks that HLA-match a target population.
EMBO Mol. Med. 5:10-17(2013)

PubMed=25122690; DOI=10.5966/sctm.2014-0015; PMCID=PMC4181394
Devito L.G., Petrova A., Miere C., Codognotto S., Blakely N., Lovatt A., Ogilvie C.M., Khalaf Y., Ilic D.
Cost-effective master cell bank validation of multiple clinical-grade human pluripotent stem cell lines from a single donor.
Stem Cells Transl. Med. 3:1116-1124(2014)

PubMed=26607962; DOI=10.1038/srep17258; PMCID=PMC4660465
Canham M.A., Van Deusen A.L., Brison D.R., De Sousa P.A., Downie J.M., Devito L.G., Hewitt Z.A., Ilic D., Kimber S.J., Moore H.D., Murray H., Kunath T.
The molecular karyotype of 25 clinical-grade human embryonic stem cell lines.
Sci. Rep. 5:17258-17258(2015)

PubMed=27345988; DOI=10.1016/j.scr.2015.12.047; PMCID=PMC4823760
Devito L.G., Petrova A., Wood V., Kadeva N., Cornwell G., Codognotto S., Stephenson E.L., Ilic D.
Generation of KCL033 clinical grade human embryonic stem cell line.
Stem Cell Res. 16:296-299(2016)

PubMed=28445466; DOI=10.1038/nature22312; PMCID=PMC5427175
Merkle F.T., Ghosh S., Kamitaki N., Mitchell J., Avior Y., Mello C., Kashin S., Mekhoubad S., Ilic D., Charlton M., Saphier G., Handsaker R.E., Genovese G., Bar S., Benvenisty N., McCarroll S.A., Eggan K.C.
Human pluripotent stem cells recurrently acquire and expand dominant negative p53 mutations.
Nature 545:229-233(2017)